tranexamic acid has been researched along with ecallantide in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giddings, JC; Hashimoto, M; Matsuo, O; Oiwa, K; Okada, K; Okada, Y; Okamoto, S; Ueshima, S; Yamamoto, J | 1 |
| Firszt, R; Frank, MM | 1 |
| Bokesch, PM; Grocott, HP; Levy, JH; Mazer, CD; Smith, PK; Szabo, G; Vetticaden, S; Wheeler, A; Wojdyga, R | 1 |
| Cole, SW; Lundquist, LM | 1 |
| Hanson, J; Portnoy, J; Shroba, J | 1 |
| Banerji, A; Bernstein, JA; Busse, P; Christiansen, S; Craig, T; Davis-Lorton, M; Frank, MM; Li, HH; Lumry, WR; Riedl, M; Zuraw, B | 1 |
2 review(s) available for tranexamic acid and ecallantide
| Article | Year |
|---|---|
An overview of novel therapies for acute hereditary angioedema.
Topics: Acute Disease; Adrenergic beta-Antagonists; Androgens; Antifibrinolytic Agents; Bradykinin; Bradykinin Receptor Antagonists; Complement C1 Inhibitor Protein; Danazol; Hereditary Angioedema Type III; Hereditary Angioedema Types I and II; Hormone Antagonists; Humans; Kallikreins; Peptides; Tranexamic Acid | 2010 |
Icatibant for the treatment of hereditary angioedema.
Topics: Angioedemas, Hereditary; Anti-Inflammatory Agents, Non-Steroidal; Bradykinin; Bradykinin Receptor Antagonists; Clinical Trials, Phase III as Topic; Complement C1 Inhibitor Protein; Humans; Peptides; Tranexamic Acid | 2013 |
1 trial(s) available for tranexamic acid and ecallantide
| Article | Year |
|---|---|
A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial).
Topics: Aged; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Double-Blind Method; Early Termination of Clinical Trials; Erythrocyte Transfusion; Europe; Female; Hemostatics; Humans; Male; Middle Aged; Peptides; Postoperative Hemorrhage; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Tranexamic Acid; Treatment Outcome; United States | 2012 |
3 other study(ies) available for tranexamic acid and ecallantide
| Article | Year |
|---|---|
Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model.
Topics: Animals; Antibodies; Arginine; Drug Antagonism; Fibrinolysin; Fibrinolysis; Fibrinolytic Agents; Kallikreins; Male; Mesenteric Arteries; Phenylalanine; Pipecolic Acids; Plasma Kallikrein; Rats; Rats, Wistar; Sulfonamides; Thrombolytic Therapy; Thrombosis; Tissue Plasminogen Activator; Tranexamic Acid; Urokinase-Type Plasminogen Activator | 2003 |
Current treatment options for idiopathic angioedema.
Topics: Adolescent; Angioedema; Antibodies, Anti-Idiotypic; Bradykinin; Female; Humans; Peptides; Tranexamic Acid | 2015 |
Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency.
Topics: Adolescent; Angioedemas, Hereditary; Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Bradykinin; Child; Complement C1 Inactivator Proteins; Complement C1 Inhibitor Protein; Danazol; Genetic Testing; Humans; Patient Care Team; Patient Education as Topic; Peptides; Recombinant Proteins; Tranexamic Acid | 2016 |